Gerdes, Sascha
Campanati, Anna http://orcid.org/0000-0002-3740-0839
Ratzinger, Gudrun
Halioua, Bruno
Krogager Eeg, Martin
Pesiridis, Georgios
Jablonski Bernasconi, Marie Y.
Lazaridou, Elizabeth
Article History
Received: 23 November 2023
Accepted: 25 January 2024
First Online: 15 February 2024
Change Date: 20 March 2024
Change Type: Update
Change Details: Formatting error in table 2 corrected
Declarations
:
: Sascha Gerdes has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies: AbbVie, Acelyrin, Affibody AB, Akari Therapeutics Plc, Almirall-Hermal, Amgen, Anaptys Bio, Argenx BV, Biogen Idec, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, Hexal AG, Incyte Inc., Janssen-Cilag, Johnson & Johnson, Klinge Pharma, Kymab, Leo Pharma, Medac, MSD, Neubourg Skin Care GmbH, Novartis, Pfizer, Principia Biopharma, Regeneron Pharma-ceutical, Sandoz Biopharmaceuticals, Sanofi-Aventis, UCB Pharma. Gudrun Ratzinger reports honoraria for lectures, training sessions or participation in advisory boards from Abbvie, Almirall, Böhringer Ingelheim, Eli Lilly, Janssen, Leo Pharma, Novartis, Pelpharma, Pfizer, UCB. Bruno Halioua has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies: Abbvie, Novartis, LEO Pharma France, Sanofi, Lilly, Amgen France. Elizabeth Lazaridou reports speaker’s or advisor’s honoraria, grants and participation in clinical trials from Abbvie, UCB, Janssen, LEO Pharma, Novartis, Pharmaserve-Lilly, Sanofi, Pfizer,Genesis Pharma, Pierre Fabre, L’Oreal. Anna Campanati has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies from Abbvie, Almirall, Böhringer Ingelheim, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, UCB, Sanofi-Aventis, Celgene, Amgen, Janssen-Cilag, Regeneron Pharmaceuticals. Martin Krogager Eeg, Georgios Pesiridis, and Marie Y Jablonski Bernasconi are employees of LEO Pharma, A/S.
: All six NIS and this post hoc analysis were sponsored by LEO Pharma and conducted according to the ethical principles derived from the Declaration of Helsinki and Good Clinical Practice guidelines. The six NIS were approved by the local institutional review board or ethics committee of each institution, and all patients provided written informed consent.